Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Identification of long-term survival-associated gene in breast cancer

Determining breast cancer biomarker status and associated morphological features using deep learning

A Comprehensive Outline Of Trastuzumab Resistance Biomarkers In HER2 Overexpressing Breast Cancer

Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center - Modern Pathology

Oncology

PDF] Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

MLO LABline Daily - Feb 22nd, 2024

Cancers, Free Full-Text

HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort - Modern Pathology

Moving Beyond Binary: Redefining HER2 Breast Cancer Classification and Treatment - Cancer Therapy Advisor

Breast cancer biomarkers

How Common Is Triple-Positive Breast Cancer?

Relevant breast cancer biomarkers at different time points in disease

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level